VCNX News and Press, Vaccinex Inc. From 09/29/23

2023-09-29 04:38:46 ET More on Vaccinex Financial information for Vaccinex For further details see: Vaccinex slumps 29%, prices $9.6M equity

ROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4...

2023-09-28 12:59:55 ET Gainers: Baudax Bio ( BXRX ) +75% . Chico's Fas ( CHS ) +63% . Aytu BioPharma ( AYTU ) +35% . Axcella Health ( AXLA ) +35% . Vaccinex ( VCNX ) +33% . Organogenesis Holdings ( ORGO ) +27% . F...

Application is based on proprietary poxvirus system that enables Hard-to-Drug Complex Proteins to be expressed at high levels in their “native conformation” so as to efficiently induce and select specific antibody-producing cells Successfully applied in proof-of-concept ev...

Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb ® application to be reviewed on September 28 at CHI's 20th Annual Discovery on Target (DOT) conference ROCHESTER, N.Y., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Vaccinex,...

2023-09-26 13:46:32 ET Gainers: Soleno Therapeutics ( SLNO ) +446% . Femasys ( FEMY ) +271% . Immunovant ( IMVT ) +101% . Intercept Pharmaceuticals ( ICPT ) +79% . Acasti Pharma ( ACST ) +35% . Applied Therapeutics ( APLT ...

"Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease” will be a podium presentation at the 16th edition of the Clinical Trials on Alzheimer’s Disease Conference to be held in Boston on October 24-27, 2023. “Inhibition of...

2023-09-22 16:40:09 ET More on Vaccinex Financial information for Vaccinex For further details see: Vaccinex implements reverse stock split to regain Nasdaq compliance

ROCHESTER, N.Y., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced that it will effect a 1-for-15 reverse...

Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Promising Interim Results for KEYNOTE-B84 Phase 2 Trial in Head and Neck Cancer ROCHESTER, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) ...